0
Abstract: Slide Presentations |

Treatment of Pulmonary Sarcoidosis With Hydroxycholoroquine: Result of A Pilot Study From India FREE TO VIEW

Rajesh Sharma, Research Associate; Randeep Guleria, Additional Professor; Anant Mohan, Senior Research Associate
Author and Funding Information

All India Institute of Medical Sciences, New Delhi, India


Chest


Chest. 2003;124(4_MeetingAbstracts):109S-b-110S. doi:10.1378/chest.124.4_MeetingAbstracts.109S-b
Text Size: A A A
Published online

Abstract

PURPOSE:  Sarcoidosis is a granulomatous disorder commonly affecting the young adults and causes bilateral hilar adenopathy as the most common pulmonary manifestation. The conventional treatment of this disorder is corticosteroids which can have serious side effects like hypertension, diabetes, cataracts, etc. Since hydroxychloroquine(HCQS) has been used safely to treat cutaneous sarcoidosis, we evaluated HCQS as a safer alternative to glucocorticoids in patients with pulmonary sarcoidosis.

METHODS:  Eleven consecutive patients with Stage II or III of sarcoidosis were administered HCQS (600mg/day, 400mg/day and 200mg/day for 2 months each respectively. The patients were evaluated at 1,3, and 6, months of therapy with clinical examination, skiagrams chest, Mantoux test, lung function tests including tests for diffusion impairment, diffusion lung capacity for carbon monoxide (DLCO).

RESULTS:  In all patients there was a marked relief in constitutional symptoms like fever and myalgias. Partial or complete resolution of hilar adenopathy and pulmonary infiltrates was also evident in all. Pulmonary function testing, done after 6 months of therapy, revealed improvement in forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) in 8 patients and DLCO in 3.FVC (% predicted) and FEV1 (% predicted) changed from a pretreatment level of 77.3±15.6 and 71.8±16.7 to 80.75 ± 6.1 and 81.6 ±19.4 respectively at 6 months.In 3 patients FVC and FEV1 remained unchanged.Mantoux test remained <2mm in all. Two patients developed diarrhea which was self limiting. There were no other complications.

CONCLUSION:  HCQS is a safe, effective and attractive alternative to coricosteroids in sarcoidsosis. However, this is a small pilot study and a larger study is needed before HCQS can be prescribed routinely in pulmonary sarcoidosis.

CLINICAL IMPLICATIONS:  Hydroxycholoroquine is an effective alternative to corticosteroids in treatment of sarcoidosis and is free from any serious side effects.

DISCLOSURE:  R. Sharma, None.

Tuesday, October 28, 2003

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543